GSK's Recently Approved Vaccine Offers Long-Term Protection Against RSV in Older Adults, New Data Reveals
Portfolio Pulse from Vandana Singh
GSK announced new data from the AReSVi-006 phase 3 trial, showing that a single dose of Arexvy vaccine is efficacious against RSV-LRTD and severe LRTD in adults aged 60 years and older over two full RSV seasons. The trial also found that revaccination after 12 months does not appear to confer additional benefit for the overall population.
June 21, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK's Arexvy vaccine shows efficacy in older adults over two RSV seasons, but revaccination after 12 months offers no additional benefit. GSK shares are up 0.78% in premarket trading.
The positive results from the AReSVi-006 phase 3 trial demonstrate the efficacy of GSK's Arexvy vaccine in older adults, which could lead to increased demand for the vaccine and potentially boost GSK's revenues. However, the lack of additional benefit from revaccination after 12 months may limit the vaccine's long-term revenue potential. The 0.78% increase in GSK's share price during premarket trading indicates that the market is reacting positively to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100